Dear Luann, Andreas and others,

Both parts are very clear to me now.  Thank you very much!

My problem was,  when I tried to simulate the differential equation model 
with parameters from ADVAN2, it did not work.  The error message is listed 
below.  This was not an issue during the model switch when D1 was not 
included in ADVAN2.  I then tried to derive the parameters from the 
differential equation model directly.  But there were >10 error messages 
like below issued.  Do you have any insight why this happens?
 

0PRED EXIT CODE = 1
0INDIVIDUAL NO.       1   ID= 2.00100000000000E+03   (WITHIN-INDIVIDUAL) 
DATA REC NO.  18
 THETA=
  4.19E+00   1.22E+01   9.10E+00   1.07E+01   1.20E+01   8.89E+00 0.00E+00 
  1.50E-03   2.63E-01   2.28E+00
  2.87E+00
 NUMERICAL DIFFICULTIES WITH INTEGRATION ROUTINE.    
 MAXIMUM NO. OF EVALUATIONS OF DIFFERENTIAL EQUATIONS,      1000000, 
EXCEEDED. 

Best regards,
Shelley

========================================
Xiao Hu (Shelley), Ph.D.
Scientist, 
Development Pharmacokinetics & Disposition
Biogen Idec, Inc.
14 Cambridge Center
Cambridge, MA 02142




Luann Phillips <luann.phill...@cognigencorp.com> 
10-Aug-2010 01:29 PM
Message Size: 6.6 KB

To
Xiao Hu <xiao...@biogenidec.com>
cc
nmusers <nmusers@globomaxnm.com>
Subject
Re: [NMusers] Translate ALAG1 and D1 in ADVAN2 to differential equations






Xiao Hu,

Part 1)
NONMEM handles the input of all doses automatically via the dataset 
structure. Therefore, generally there is no need to initialize 
compartments or to code infusion rates in the $DES block. An exception 
to this rule is when you are dosing or modeling endogenous substances. 
Assuming your drug is not an endogenous substance, the differential 
equations for ADVAN2 with ALAG1 and D1 are shown below (using ADVAN6).

Part 2)
"I'm not very clear what's the meaning of D1 and KA when both are 
modeled."

Based upon the ADVAN that you are using, NONMEM is putting the dose into 
the depot compartment as a constant rate infusion with a duration of D1 
(hours, days, etc.). It starts the infusion into the depot compartment 
at time=ALAG1 (hours,days, etc.) after each dose. The dose is then 
transferred from the depot compartment to the central compartment using 
a first-order process (Ka 1/hr or 1/day, etc.)

I hope this information helps,

Luann Phillips

---------------------------------------------

Example Code:

$SUBROUTINES ADVAN6 TOL=5

$MODEL
COMP=(DEPOT,DEFDOSE)
COMP=(CENTRAL,DEFOBS)
COMP=(PD1)
etc.

$PK

     KASC=THETA(4)
     VSC=THETA(5)
     CLSC=THETA(6)
     LGSC=THETA(8)

     MU_4=KASC
     MU_5=VSC
     MU_6=CLSC
     MU_8=THETA(11)

     SD=THETA(9)
     SIG=SD

     KA=EXP(MU_4+ETA(4))
     V=EXP(MU_5+ETA(5))
     CL=EXP(MU_6+ETA(6))
     K=CL/V
     S2=V/1000; DOSE IN 1000 U, CONC in U, VOLUME IN mL
     ALAG1=LGSC*EXP(ETA(10))
     D1=EXP(MU_8+ETA(8))

$DES

DADT(1) = -KA*A(1)
DADT(2) =  KA*A(1) - K*A(2)
DADT(3) = equations for PD cmt 1

etc.

--------------------------------------------------



Xiao Hu wrote:
> 
> Dear NMusers,
> 
> I'm using ADVAN2 to model the PK of a drug.  To best fit the profile, 
> the model includes ALAG1 and D1. For the next step, the ADVAN2 needs to 
> be translated into differential equation to include a PD compartment. 
>  How should I write the differential equation for ALAG1 and D1?  As you 
> can see, there is Ka in the ADVAN2 model.  I'm not very clear what's the 

> meaning of D1 and KA when both are modeled.  Any hint or previous link 
> would be appreciated. Thanks in advance!
> 
> $SUBROUTINES ADVAN2
> $PK 
> 
>    KASC=THETA(4)
>    VSC=THETA(5)
>    CLSC=THETA(6)
>    LGSC=THETA(8)
> 
>    MU_4=KASC
>    MU_5=VSC
>    MU_6=CLSC
>    MU_8=THETA(11)
> 
>    SD=THETA(9)
>    SIG=SD
> 
>    KA=EXP(MU_4+ETA(4))
>    V=EXP(MU_5+ETA(5))
>    CL=EXP(MU_6+ETA(6))
>    K=CL/V
>    S2=V/1000; DOSE IN 1000 U, CONC in U, VOLUME IN mL
>    ALAG1=LGSC*EXP(ETA(10))
>    D1=EXP(MU_8+ETA(8))
> 
> Final parameter estimates:
> 
> $THETA
>    12  ;THETA5
>    8.89   ;THETA6
>    0.0015;THETA8
>    0.263 ; THETA9 
>    2.87; THETA11
> 
> Best regards,
> Shelley
> 
> ========================================
> Xiao Hu (Shelley), Ph.D.
> Scientist,
> Development Pharmacokinetics & Disposition
> Biogen Idec, Inc.
> 14 Cambridge Center
> Cambridge, MA 02142

Reply via email to